US5053399A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Myo-inositol analogs and methods for their use
Assignee: University of Pittsburgh
•
Filing: 1990-10-12
•
Granted: 1991-10-01
•
Expires: 2010-10-12
Abstract
Abstract The present invention relates to a method for inhibiting the phosphatidylinositol cycle in a cell by contacting the cell with certain myo-inositol analogs. Such myo-inositol analogs can also be utilized to treat phosphatidylinositol cycle-dependent conditions. The present invention also provides novel myo-inositol analogs.
Inventors
- 👤 Alan P. Kozikowski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 19:30
CPC Classifications
C; C07; C07C; C07C323/00; C07C323/10; C07C323/17; A; A61; A61K; A61K31/00; A61K31/045; A61K31/047; C07C211/00; C07C211/33; C07C211/34; C07C211/37; C07C247/00; C07C247/14; C07C255/00; C07C255/45; C07C255/46; C07C35/00; C07C35/02; C07C35/08; C07C35/14; C07C35/16; C07C35/48; C07C2601/00; C07C2601/12; C07C2601/14
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
136 words
A method for inhibiting the phosphatidylinositol cycle in a cell which comprises contacting said cell with a compound represented by the formula I: ##STR17## wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is each independently selected from the group consisting of OH, F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN; with the proviso: (i) four or five of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH; and (ii) if said R 4 , R 5 or R 6 is F, Cl, Br or I then four of the said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
Claim 2
Independent Claim
136 words
A method for inhibiting the phosphatidylinositol cycle in a cell which comprises contacting said cell with a compound represented by the formula I: ##STR17## wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is each independently selected from the group consisting of OH, F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN; with the proviso: (i) four or five of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH; and (ii) if said R 4 , R 5 or R 6 is F, Cl, Br or I then four of the said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
Claim 3
Dependent Claim
13 words
The method according to claim 1 wherein said method is carried out in-vitro.
Claim 4
Dependent Claim
13 words
The method according to claim 1 wherein said method is carried out in-vivo.
Claim 5
Dependent Claim
29 words
The method according to claim 1 wherein five of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
Claim 6
Dependent Claim
30 words
The method of claim 4 wherein one of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is F or SH.
Claim 7
Dependent Claim
27 words
The method of claim 5 wherein one of said R 1 , R 2 , R 3 , 4 , R 5 and R 6 is F.
Claim 8
Dependent Claim
23 words
The method of claim 4 wherein R 1 is selected from the group consisting of F, SH, SeH, Cl, Br, I and CN.
Claim 9
Dependent Claim
12 words
The method of claim 7 wherein R 1 is F or SH.
Claim 10
Dependent Claim
10 words
The method of claim 8 wherein R 1 is F.
Claim 11
Dependent Claim
23 words
The method of claim 4 wherein R 3 is selected from the group consisting of F, SH, SeH, Cl, Br, I and CN.
Claim 12
Dependent Claim
12 words
The method of claim 10 wherein R 3 is F or SH.
Claim 13
Dependent Claim
10 words
The method of claim 10 wherein R 3 is F.
Claim 14
Dependent Claim
28 words
The method of claim 1 wherein four of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
Claim 15
Dependent Claim
39 words
The method of claim 13 wherein two of said R 1 , R 4 and R 5 are independently selected from the group consisting of F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN.
Claim 16
Dependent Claim
34 words
The method of claim 14 wherein said R 4 and R 5 are independently selected from the group consisting of F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN.
Claim 17
Dependent Claim
51 words
The method of claim 13 wherein two of said R 1 , R 2 , 3 , R 4 , R 5 and R 6 are selected from the group consisting of F and SH; F and NH 2 ; NH 2 and SH; SH and SH; and F and F.
Claim 18
Dependent Claim
30 words
The method of claim 16 wherein two of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are F and F.
Claim 19
Independent Claim
142 words
A method for treating phosphatidylinositol cycledependent conditions in a mammal which comprises administering to said mammal an inositol phosphate cycle inhibiting amount of a compound represented by formula I: ##STR18## wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is each independently selected from the group consisting of OH, F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN; with the proviso: (i) four or five of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH; and (ii) if said R 4 , R 5 or R 6 is F, Cl, Br or I then four of the said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
Claim 20
Independent Claim
142 words
A method for treating phosphatidylinositol cycledependent conditions in a mammal which comprises administering to said mammal an inositol phosphate cycle inhibiting amount of a compound represented by formula I: ##STR18## wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is each independently selected from the group consisting of OH, F, N 3 , NH 2 , SH, SeH, Cl, Br, I and CN; with the proviso: (i) four or five of said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH; and (ii) if said R 4 , R 5 or R 6 is F, Cl, Br or I then four of the said R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are OH.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-30 | 1995-04-01 | 1995-10-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-30 | 1999-04-01 | 1999-10-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-30 | 2003-04-01 | 2003-10-01 | $7700.00 | Window Closed / Lapsed |